CF PharmTech, Inc. (02652) disclosed a share repurchase transaction dated 26 February 2026. According to the announcement, 43,000 shares were repurchased on the Hong Kong Stock Exchange at a highest price of HKD 38.48 and a lowest price of HKD 37.88, with an aggregate paid amount of HKD 1.64 million. Following the transaction, the total number of treasury shares increased to 466,000, while the number of issued shares (excluding treasury shares) stood at 301.76 million. The total number of issued shares, including treasury shares, remained at 302.22 million.

The repurchase was conducted under a mandate granted on 16 December 2025, which authorized the repurchase of up to 30.22 million shares. Information in the announcement also indicated that share issuance or treasury-share disposal is restricted until 28 March 2026, aligning with relevant regulatory provisions.